In an interview last week, Larry Cohen CEO of Health 2047, the American Medical Association’s venture studio noted that digital health programs have proven to do a good job of improving patient outcomes but only for certain groups. As technology continues to advance, he urged healthcare leaders not to underestimate the effectiveness of engaging patients by having boots on the ground.
Called RecoverX, the company will leverage AI to mine evidence-based research, medical charts, patient conversations and test results and provide clinical insights for clinicians in real time.
Apr 1, 2021 12:02pm
Phenomix Sciences blood-based test uses phenotype-driven multi-omics technology to predict responses to obesity interventions the Food and Drug Administration has approved. (vadimguzhva/GettyImages)
The American Medical Association innovation subsidiary Health2047 has spun off a company that uses personalized medicine to fight obesity.
Phenomix Sciences is a phenotype testing company that carries out the AMA’s mission to confront chronic diseases such as obesity.
Phenomix uses a blood test called MyPhenome that it has licensed from the Mayo Clinic to allow doctors to prescribe individualized therapies. MyPhenome measures DNA as well as a person’s metabolites and hormones. These biomarkers make up a person’s phenotype, according to Phenomix.